Home » FDA Gives Another Go-Ahead for Cancer Drug Lynparza
FDA Gives Another Go-Ahead for Cancer Drug Lynparza
The FDA granted another approval for Lynparza (olaparib), clearing the AstraZeneca and Merck oncology drug for maintenance treatment of adults with BRCA-mutated advanced ovarian cancer.
The approval is for adult patients who have deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to first-line, platinum-based chemo.
The approval was based on positive results from a Phase 3 trial that saw Lynparza reduce the risk of disease progression or death in patients by 70 percent.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May